Multiple Myeloma Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increase in the Prevalence of Multiple Myeloma
   3. Market Restraints
      1. High Treatment Costs
      2. Limited Treatment Options for Refractory Cases
   4. Market Opportunities
      1. Rise in Initiatives Taken by Government and Non-Profit Organizations for the Treatment of Blood Cancer and Multiple Myeloma
   5. Market Trends
      1. Precision Medicine and Targeted Therapies
      2. Immunotherapy Advancements
5. MARKET SEGMENTATION
   1. By Type
      1. Smouldering Multiple Myeloma
      2. Active Multiple Myeloma
   2. By Treatment
      1. Medications
      2. Proteasome Inhibitors
      3. Bortezomib
      4. Ixazomib
      5. Carfilzomib
      6. Histone Deacetylase (HDAC) Inhibitors
   3. By Diagnosis
      1. Blood Tests
      2. Bone Marrow Biopsy
      3. Urine Tests
      4. Imaging Tests
      5. X-ray
      6. Magnetic resonance imaging (MRI)
      7. Positron Emission Tomography (PET)
   4. By Dosage Forms
      1. Capsule
      2. Tablets
      3. Injections
      4. Others
   5. By Route of Administration
      1. Oral
      2. Parenteral
         1. Intravenous
         2. Others
      3. Others
   6. By End-Users
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
   7. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
      4. Others
   8. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amneal Pharmaceuticals LLC. (US)
      2. Allergan (Ireland)
      3. AstraZeneca (UK)
      4. Aurobindo Pharma (India)
      5. Abbott (US)
      6. AbbVie Inc. (US)
      7. Bausch Health Companies Inc. (Canada)
      8. Bayer AG (Germany)
      9. Cipla Inc. (US)
      10. GlaxoSmithKline plc (UK)
      11. Eli Lilly and Company (US)
      12. F. Hoffmann-La Roche Ltd. (Switzerland)
      13. Fresenius Kabi AG (Germany)
      14. Hikma Pharmaceuticals PLC (UK)
      15. Johnson & Johnson Private Limited (US)
      16. LEO Pharma A/S (Denmark)
      17. Lupin (India)
      18. Mylan N.V. (US)
      19. Merck & Co., Inc. (US)
      20. Merck KGaA (Germany)
      21. Novartis AG (Switzerland)
      22. Pfizer Inc. (US)
      23. Sanofi (France)
      24. Sun Pharmaceutical Industries Ltd. (India)
      25. Teva Pharmaceutical Industries Ltd. (Ireland)
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Multiple Myelomamarket?

The global market of Multiple Myeloma is projected to reach USD 46.9 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Multiple Myelomamarket?

The global Multiple Myeloma market has an estimated annual growth rate of 6.5% .

Q.3. What are the recent trends of Multiple Myelomamarket?

Precision medicine and targeted therapies and immunotherapy advancements are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Multiple Myeloma?

The major companies profiled in this report include Amneal Pharmaceuticals LLC. (US), Allergan (Ireland), AstraZeneca (UK), Aurobindo Pharma (India), Abbott (US), AbbVie Inc. (US), Bausch Health Companies Inc. (Canada), Bayer AG (Germany), Cipla Inc. (US), GlaxoSmithKline plc (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (UK), Johnson & Johnson Private Limited (US), LEO Pharma A/S (Denmark), Lupin (India), Mylan N.V. (US), Merck & Co., Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Ireland), among others.

Q.5. Which region is estimated to held highest CAGR inMultiple Myelomamarket?

North America is estimated to hold biggest share in the market for Multiple Myeloma.